Hengzhou Zhu

Hengzhou Zhu

Auto-generated profile, based on publicly available information

Hengzhou Zhu

Department of Oncology Nanjing University of Chinese Medicine Wuxi Affiliated Hospital: Wuxi Hospital of Traditional Chinese Medicine Wuxi P.R. China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2025 in Drug Resistance Updates
Verified
Journal Article
Open access
HZHengzhou Zhu
Hengzhou Zhu
YTYuanyang Tian
Yuanyang Tian
HCHaoyan Chen
Haoyan Chen
YQYiyang Qian
Yiyang Qian
JLJiahui Li
Jiahui Li
CJChunhui Jin
Chunhui Jin
Targeting DNA damage response (DDR) pathways has become a promising strategy for overcoming tumor drug resistance, particularly in cancers with DNA repair defects. DDR pathways, including homologous recombination (HR), non-homologous end joining (NHEJ), base excision repair (BER), and mismatch repair (MMR), are essential for maintaining genomic stability. However, resistance to DDR-targeted therapies, such as PARP inhibitors, often arises due to tumor adaptation through various mechanisms. These include HR pathway restoration, mutations in DDR proteins, altered drug metabolism, and the activation of compensatory repair pathways. This review provides a comprehensive analysis of the molecular mechanisms underlying DDR resistance in tumors and explores the clinical implications of these mechanisms in the context of ongoing therapeutic strategies. We also discuss emerging approaches to overcome DDR resistance, including the development of novel DDR inhibitors, combination therapies, and precision medicine approaches based on biomarkers. Furthermore, we highlight future research directions, focusing on the use of advanced technologies, such as CRISPR screening, single-cell sequencing, and artificial intelligence, to uncover new targets and therapeutic strategies to combat DDR-related drug resistance.

23 November 2024 in Journal of Ethnopharmacology
Verified
Journal Article
Open access
YJYi Ji
Yi Ji
LLLi Li
Li Li
WLWenting Li
Wenting Li
LLLiu Li
Liu Li
YMYanxia Ma
Yanxia Ma
WMWu Mianhua
Wu Mianhua
The Xiaoai Jiedu recipe (XJR) is a traditional Chinese medicine formulation used in clinical settings to treat liver cancer. It has shown promising effectiveness by combining herbal and animal-derived ingredients, offering a new approach to cancer treatment. However, its mechanism of action is poorly understood. The molecular processes underlying the inhibitory effects of the XJR on hepatocellular cancer (HCC) were investigated. The primary chemical components of XJR and associated disease targets relevant to HCC were anticipated and compiled using a database. The potential targets and processes by which XJR influenced HCC were investigated using GO and KEGG enrichment analyses, as well as protein-protein interaction (PPI) networks. Transmission electron microscopy, laser confocal microscopy, and Western blotting were used to evaluate autophagy, while CCK-8 assays measured cell viability and Western blotting and flow cytometry evaluated apoptosis. In vivo assays were conducted employing an HCC xenograft mouse model. Network pharmacology analysis identified 456 intersecting targets between XJR and HCC. The top five active components are quercetin, cholesterol, jaceosidine, eupafolin, and oleanolic acid. The key targets include TP53, AKT1, IL6, EGFR, SRC, HSP90AA1, TNF, IL1B, MYC, and CASP3. Additionally, the autophagy pathway was found to be one of the main pathways through which XJR intervenes in HCC. The increased quantity of autophagosomes and autolysosomes, the overexpression of Beclin1 and LC3A/B-II proteins, and the downregulation of P62 all suggest that XJR stimulated autophagy in HCC cells. Functional tests employing pathway-specific activators and inhibitors and siRNA-based knockdown demonstrated that XJR promoted autophagy by blocking AKT/mTOR signaling. Furthermore, XJR reduced the viability of HCC cells and promoted apoptosis by upregulating apoptosis proteins. Autophagy inhibitors and Beclin1 silencing reversed these effects. Research conducted in vivo showed that XJR activated autophagy through the AKT/mTOR axis, thereby markedly reducing tumor growth and inducing tumor cell demise. These studies show that XJR activates autophagy in both cellular and animal models to induce apoptosis and decrease HCC cell proliferation, as shown by network pharmacology and verification assays. Further, these findings provide experimental evidence that the anti-tumor activity of XJR involves autophagy stimulation.

19 October 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
HCHaoyan Chen
Haoyan Chen
RGRenjun Gu
Renjun Gu
YWYan Wu
Yan Wu
SLSiqi Li
Siqi Li
XZXinyan Zhang
Xinyan Zhang
HLHengrui Liu
Hengrui Liu
RNA N6-methyladenosine (m6A) represents a major epitranscriptomic regulatory layer governing cancer-associated transcriptional programs and immune cell states, but how m6A-associated molecular contexts are captured in circulating cell-free DNA (cfDNA) fragmentomes remains unclear. Here, we integrated RNA perturbation, RNA modification, chromatin profiling, tissue transcriptomics, and single-cell analyses to define m6A-associated regulatory programs, including a Pm program comprising 1,758 protein-coding gene promoter regions and a Pc program comprising 378 chromatin-associated regulatory RNA regions, and characterized their plasma cfDNA fragmentation patterns in 99 longitudinal samples from 33 patients with advanced non-small cell lung cancer (NSCLC) and 10 healthy individuals. Comprehensive analyses incorporating multiple-testing correction, leave-one-individual-out evaluation, and blood collection date sensitivity assessment identified stable cfDNA signatures across reference end motifs, regional fragmentation features, and immune-related footprints. Among baseline-associated features, 83 end motifs, 7 regional features, and 9 immune footprints remained significant after correction, while 52 end motifs and 6 regional features retained support across sensitivity analyses. Pm whole-target equal-weight coverage depletion and central cleavage features showed consistent directions across analyses, and 34 end motifs were associated with ctDNA fractions. Pc regional RNA responses showed a weak positive correlation with H3K27ac changes (rho = 0.207, q = 6.97 × 10-5), while tissue and donor-level single-cell analyses linked these programs to proliferative and immune cell states. Together, these findings indicate that m6A-associated regulatory programs capture integrated epitranscriptomic, transcriptional, chromatin, and cellular-state contexts that are reflected in plasma cfDNA fragmentomes. This study establishes a framework connecting RNA epitranscriptomic states with circulating fragmentomic features and provides candidate biomarkers and analytical strategies for patient-matched multimodal liquid biopsy applications in precision oncology.

26 August 2026 in Cell Biochemistry and Function
Verified
Journal Article
Open access
PDF file
QTQuan Tang
Quan Tang
DNDong Niu
Dong Niu
HLHe Li
He Li
HZHeng Zhou Zhu
Heng Zhou Zhu
CJChun Hui Jin
Chun Hui Jin
XZXiao Dan Zhu
Xiao Dan Zhu
Breast cancer (BC) is a highly heterogeneous malignancy with complex molecular mechanisms, highlighting the need for effective biomarkers and therapeutic targets. The Fritillariae Thunbergii Bulbus–Bolbostemmatis Rhizoma (ZBM–TBM) herb pair has been used in the treatment of BC, although its potential molecular mechanisms remain incompletely understood. In this study, an integrated strategy combining transcriptomic analysis, machine learning, liquid chromatography–tandem mass spectrometry (LC–MS/MS), network pharmacology, molecular docking, molecular dynamics (MD) simulations, and single‐cell virtual knockout analysis was employed to identify BC‐associated molecular biomarkers and explore the potential mechanisms underlying the effects of ZBM–TBM. Integration of weighted gene co‐expression network analysis with least absolute shrinkage and selection operator regression, random forest, and support vector machine–recursive feature elimination identified EPCAM as the only common core gene. EPCAM was significantly upregulated in BC tissues and showed favorable diagnostic performance (AUC = 0.903), while high EPCAM expression was associated with shorter overall survival (log‐rank P = 0.032). Functional analyses indicated that EPCAM was associated with tumor‐related and immune‐related biological processes, including cell cycle regulation, DNA replication, and immune regulation. LC–MS/MS analysis identified 32 major active constituents of ZBM–TBM, and subsequent network pharmacology analysis identified 33 overlapping targets and 10 hub genes enriched in multiple tumor‐ and immune‐related signaling pathways, including the Notch, IL‐17, HIF‐1, and TGF‐β signaling pathways. Although ZBM–TBM did not directly target EPCAM in the predicted target network, computational analyses indicated functional associations between EPCAM and hub gene‐associated regulatory networks. Molecular docking and MD simulations further suggested that peiminine may represent a potential active constituent, exhibiting favorable predicted binding characteristics with multiple candidate targets, particularly AURKA. Single‐cell virtual knockout analysis showed that computational perturbation of AURKA was associated with alterations in cell cycle‐, extracellular matrix‐, and cell adhesion‐related processes, supporting its potential functional relevance at the cellular level.